Many progresses for the treatment of multiple myeloma have been made since last decade.The application of novel target agents has brought the treatment of multiple myeloma into a new era.The outcomes of multiple myeloma have also been greatly improved with mechanism-based combinations of various agents.It is emphasized that clinicians should better understand the biological characteristics of myeloma cells and the anti-myeloma mechanisms underlined.In this review,the author will review the current status and make a prospective discussion in this field.

In present study,we detected HLA-DR antigens on monocytes of 28 patients with mutiplemyelomas (MM) and 20 normal controls with indirect immunofluorescent staining and flow cy-tometric technique.It was descovered that HLA-DR~+ monocytes of patients (33.63?16.24%)were greatly lower than these of normal controls (61.45?10.1% ) (P

Hematopoietic Stem Cell Transplantation ; Humans ; Multiple Myeloma ; pathology ; therapy ; Neoplasm Staging ; Transplantation, Autologous

Diagnostic Imaging ; Humans ; Multiple Myeloma ; diagnosis ; therapy

Humans ; Multiple Myeloma ; Neoplasm Recurrence, Local

Purpose:To explore the in vitro effects of apoptosis induction of 2-methoxyestradiol(2ME2),an estrogen derivative on primary myeloma cells and hematopoietic precursors from multiple myeloma patients. Methods:The primary myeloma cells and hematopoietic precursors from 14 multiple myeloma patients were examined determine apoptosis cells in situ by terminal-deoxynucleotidyl transferase mediated dUTP nick end labeling(TUNEL)assay. Results:After co-cultured with different concentrations (1,4,16?mol/L) 2 ME2 for 48h respectively,apoptotic ratios of myeloma cells were 10.5? 1.2%,21.2?2.3%,36.8?3.6% respectively ,which shows a concentration- dependence.In comparision with the control group,the difference is of statistical significance(P0.05). Conclusions:2ME2 could electively induce apoptosis of primary myeloma cells from myeloma patients and has little apoptotic effect on granulocytic,erythrocytic and lymphocytic cells in the bone marrow.

Immunocompromised hosts(ICH)is a particular population drawing more current attention with the susceptibility to infections,especially to the opportunistic pathogens.When infections occur in ICH,the mortality increases significantly.The clinical manifestations and radiological characteristics are untypical and non-specific,so the correct diagnosis in good time is arduous.But the rapid and correct diagnosis is primary and principle to lower the mortality of the infections of ICH,so this article aims to generalize the diagnosis phronesis of pulmonary infections of ICH-to elaborate the key points of the assessment and evaluation of ICH;the principle of differential diagnosis of pulmonary infections in ICH;clinical evaluation program of the pulmonary infiltration in ICH. Abstract:Summ ary:Immunocomprom ised hosts(ICH) is a particu lar popu lation draw ing more current attention w ith the susceptib il-ity to infections,espec ially to the opportun istic pathogens.W hen infections occur in ICH,the mortality increases sign ifi-cantly.The c lin icalm an ifestations and rad iological characteristics are untyp ical and non-spec ific,so the correct d iagnosis in good tim e is arduous.But the rap id and correct d iagnosis is prim ary and princ ip le to lower the mortality of the infections of ICH,so th is artic le aim s to generalize the d iagnosis phronesis of pu lmonary infections of ICH-to elaborate the key points of the assessm ent and evaluation of ICH;the princ ip le of d ifferential d iagnosis of pu lmonary infections in ICH;c lin ical e-valuation program of the pu lmonary infiltration in ICH.

The treatment of multiple myeloma has become possible in the era of novel agents. Novel agents have dramatically improved the response rates of multiple myeloma (MM) and have extended the survival of patients even if MM remains an incurable disease. De-termining the treatment goals of MM has become a major challenge for clinicians in the era of novel agents. Many results show the correlation between response depth and patients' survival. Complete remission (CR), stringent CR, phenotypic CR, and CRs at the molecular and PET-CT levels are being explored and becoming the goals of MM treatment. Doctors should balance efficacy with adverse effects in daily clinical practice to avoid the blind pursuit of a high and deep response rate.

Multiple myeloma (MM) is one of hot topics in the 54th ASH annual meeting.There were over 700 myeloma related abstracts in 2012.The abstracts reflected recent progress of MM researches and fell into 4 major groups,including new drug trials,frontline options,biology and molecular genetics,and myelodysplastic syndrome prior to the onset of myeloma and myeloma treatment.

Multiple myeloma (MM) is a genetically complex disease that is becoming more common in today' s aging population.In the 18th European Hematology Association (EHA) annual meeting,there were a number of key topics focusing on the development of MM from intraclonal heterogeneity,novel therapeutic agents,and relapse and refractory MM therapy,etc.